and afternoon. Thank you, Brian, good
These including Pharmaceutical and another earnings had growth pharmaceutical quarter our with operations McKesson share an to results solid mentioned, our in oncology Canadian increase Brian full leading International our expectations, the guidance. capabilities U.S. specialty exceeded the continued As segment. that within in resulting results segment, and distribution year our reflect per our
billion consecutive repurchase strategic $XX XXXX. the approximately to pleased Directors $X and approved authorization total to our continue demonstrate capital that second, priorities of XX% in the in the an increases; to share shareholders. that increase actions deployment a dividend execution dividend additional eighth of for as as also and value Board management quarterly share two the July: the have of of July year confidence of focus actions $X.XX Board bringing share, These drive authorization, I'm on billion to the repurchase marking per we our first, to of our
our of adjusted Pharmaceutical a level revenues outlook. increase Consolidated consolidated were results, the the segment, in from account growth our with volumes customers I'll from to refer by increased and unless today on resulting products, comments segment an national results conclude followed with GLP-X start prescription $XX.X at state billion, otherwise. My the update I an higher U.S. led X%, medications. and retail specialty including by volumes, review
$X.X Pharmaceutical offset by segment, Gross distribution volumes an a Canadian contributions lower billion, result from International the Medical-Surgical of including was our higher in primary business our of growth U.S. in profit channel care segment. in segment. and Solutions These X%, distribution specialty the the business Solutions increase partially within included the primarily Provider were
first joint related X% by the -- Pharmaceutical investment segment. results enterprise lapping in also the [indiscernible] to across year million fiscal to support corporate savings $X the U.S. and of pretax XXXX. equity to by of increased expenses $X.X $X.X losses principally XX%, pretax impacted McKesson were of prior the profit million an driven and billion, Operating costs SCRI billion, Ventures compared associated technology of growth quarter integration result $XXX investments venture in increased with Year-over-year gains expenses to the Operating increase solutions. of in included was
extinguishment lower the in throughout primary from a partially portfolio expense quarter Solutions U.S. the debt loan care Medical-Surgical from the higher million, our and increase an average channel on million. over balances by was Year-over-year results segment, year in of prior $X benefited the year, Pharmaceutical prior of $XX continued segment. gain across Interest the offset growth volumes resulting
The quarter the the driven net of recognition discrete by tax rate benefits XX%, effective $XXX million tax for quarter. of was in the
in the As a million of we prior year. a quarter tax $XXX reminder, net had discrete first the of benefit
the discrete items previously, amount annual guidance and difficult As predict. as are we've rate effective discussed we of provide tax to tax timing
profit segment. diluted our with shares outstanding of consolidated weighted of $X.XX, investments, a million, earnings Wrapping expectations, X%. by diluted associated equity per up a average quarter Pharmaceutical X% operating decrease driven was U.S. to the McKesson our share First and increased growth in Ventures XXX.X lower pretax results, share count gains ahead
Turning customer Pharmaceutical. quarter solid results. continued Once growth. results Pharmaceutical found sustainable segment through first higher profit U.S. revenue volumes and all first retail were growth national across ability again, reflects X%. drive an to of segments quarter XX segment starting U.S. positive It Slides on Revenue operating and increased delivered to X $XX.X and leading and our the be volumes, to including can trends, long-term momentum demonstrate medications. utilization Revenues from billion, customers GLP-X growth. account specialty products, prescription increase with
medication revenues quarter, an billion, the $X.X $X.X GLP-X constraints XX% XX% GLP-X the moderated On growth year-over-year, GLP-X or increased for however, of In variability for quarter. were billion $X.X We when revenues from supply in prior with a compared or medications medications approximately the billion sequential quarter-to-quarter. to continued increase basis, year. anticipate as
the of $XXX driven increased products X% profit specialty by systems. in distribution health and growth operating the For to quarter, providers to million,
U.S. to grow assets platform deliver for segment, Pharmaceutical and comprehensive leading continues value patients. the Within our and customers oncology of
oncology further site Oncology in our strengthened provider Network U.S. ongoing clinical venture, investments X,XXX differentiate increasing insight and Oncology quarter. capabilities, further X% with setup. through includes by our an data the the visits More solutions, services, accelerated Sarah growth Our in has broad trial trial in through experience the Ontada platform clinical solid trial clinical same joint than continued capabilities. set U.S. GPO matching, to of Institute and providers which Cannon including Research a capabilities Network
we're the our intend We priorities. seeing strategic and oncology our and sustain remain to excited against differentiated investment progress leading growth about and offerings ongoing
to Moving delivered both operating to Prescription billion profit Technology of revenues $X.X and $XXX year. prior flat Technology Prescription segment Solutions of million, Solutions. the
our in growth in First and solutions, our for quarter results logistics. affordability services technology growth reflect third-party growth including sequential demand across e-voucher Revenue including included products, e-prescribe. increased XX%
were had segment product results in due on lower approximately delays, X% quarter. revenue which an these drug growth to the anticipated However, than impact launch
solutions transactions the business. Operating at grow impacted due remain long-term provide and to an support profit annual will operating across or mix contributions by the on that was profit access program lower target across we the our above growth of our services to expenses growth from rate basis. access higher and We segment the future confident
Turning to Medical-Surgical Solutions.
were the including the extended segment were offset of customer operating across pharmaceuticals, Revenues product by $X.X higher First quarter increase demand and specialty year results was X%, of of a prior volumes volumes by lapping decrease this XX%. lower below an product million, These expectations. mix our in and primary in billion, profit of care nutritional and results were driven shifts, channel, strength the care channel. $XXX
to million the International the prior let portfolio million address by increase or and fiscal XX%, or higher losses volumes compared pretax quarter increase the million, of $X.X segment corporate Next, an per investments in Canadian expenses Ventures an in were was me Wrapping of $XXX operating equity first the profit share $X compared driven related of $XXX business distribution our to X%, share of in within results. the $X.XX year. million included $XX were billion, to up XXXX. gains $X.XX quarter, Revenues McKesson review, our pretax which per of pharmaceutical
magnitude, we've on for gains the As and may investment discussed, the McKesson financials influenced previously can and consolidated be of each vary performance investment. quarter-to-quarter, Ventures in timing can by each which which result impact losses, individual
quarter deployment, capital cash and to $X.X me cash which ended in found Slide Let cash equivalents. on with turn can We XX. and the be billion
capital For negative quarter, which cash included flow $XXX billion, million the of in expenditures. had $X.X first free we
We onboarding $XX of returned working cash free and included million which in Pharmaceutical flow $XXX investments of shareholders, tax impacted of the timing and support customers U.S. cash In new repurchases the by the segment. in $XXX to share payments. of the million was capital quarter, to dividend payments million
can resulting a ends and, the capital cash quarter-to-quarter. vary each therefore, of cash position, the timing, can working a be on our which week As includes quarter from impacted reminder, metrics by flows the day and that
discuss me our outlook. let XXXX Now fiscal
progress across the broad priorities, We our make against leveraging strategic our continue capabilities to enterprise.
of our our result are per confidence we and year, to over XXXX first to adjusted the $XX.XX $XX.XX. earnings diluted quarter in a the outlook balance share for the As of range fiscal guidance raising performance
remain health remainder our assets fiscal we a services Looking in XXXX, company. of our to as ahead and and strategy services care to advance McKesson differentiated biopharma confident the oncology diversified
with capabilities and portfolio of me and Let we led oncology our over the of customers, have breadth start our segments. our first In across quarter, the assets U.S. oncology including experienced momentum Pharmaceutical The for last across segment, strong X our broad partners years. to shareholders offering. value creation leading our
a the continuation U.S. for segment this Pharmaceutical outlook XXXX of is fiscal Our momentum.
the also dedicated effort that in Optum went with July XXXX. employees, our distribution outlook Thanks contract the of July. into contemplates Our a onboarding effect we seamless impact experience in from of delivered to
with not As quarter outlined, first this we start-up previously contract were costs implementation associated material to results.
during However, capital we of quarter start date. working the contract made in investments in advance the
and XX% X% We are to is increase anticipate and prior and expand strong value lower anticipate operating XX%. with volumes to including XX%. distribution to When anticipate will this which profit we a includes our we to relationship compared customer our branded testament lower sourcing guidance, contribution for to pleased We pharmaceuticals, revenues Pharmaceutical capabilities, leading to increase from distribution pharmaceutical U.S. Optum, our now proposition. HUMIRA,
to for delays. the prior to launch the the quarter decline outlook XX% Prescription Technology the first increase and XX%, operating XX% reflects product and lower-than-anticipated to In Solutions segment to The of results from modest the revenues we a segment, guidance. anticipate profit increase XX% impact updated
the access part of programs prior services access and quarter, product growth delays first our and authorization GLP-X year, driven volatility our rate a in by shortages. various demonstrated to and including related across solutions, to for medications, including transactions the mix prior the volumes demand compared During of slower
expectations than were the first quarter. in our lower These results
communicated, As growth we've remain long-term in previously on rate annual basis. we the targets confident an
shift to growth several to which annual product that for and the investments of we include that the could in fiscal of of the provide or new our quarter; our size fourth as quarter-to-quarter, However, trends; result customers the support matures, by verification requirements services program products this product utilization other programs the in from factors supply and anticipate we our product will termination; vary evolution it expand delays timing that launches; and driven and a occur and the a support program portfolio. trajectory drug shortages; trajectory segment timing in
demand solid solutions and market adherence patients' suite improve for help that medication our biopharma see of We well services access, cycle support differentiated affordability of as products. their to as and the help life throughout manufacturers to
modestly differentiated solutions to and of used providers depth We can pharmacies. market-leading build growth of seamlessly investment continued above our remain be continue confident our that the assets, long-range technology-enabled line in us and or position and We workflow for in services targets. innovation in capabilities payers, that
Moving to the X%. to Medical-Surgical range increase X% of X% operating initial X% of to We to profit Solutions. low guidance to and anticipate revenues at end be the
the covering environment the been volatility sites dynamic across care. the the and customers has last COVID, care including of Over years, Medical-Surgical primary and experienced the few products period and channel within
McKesson's and led breadth strong unparalleled performance. capabilities to of services
primary general normalized, to care noted market sales market operating conditions instances in the As This quarter. have channel. first we've and in lower led contributions of profit the weakness
the will from continue through market. trends the we that are first quarter. seeing these reflects we the second trends the results full updated year in And Our and quarter outlook the anticipate
operational Medical-Surgical to noted in within optimization and efficiencies efforts. market announcing the series the are initiatives of remarks, we conditions his Brian response cost a drive in today, segment Solutions increase As to
great these in across invest the serve patients. improved addition and In alignment our delivering to partners to while performance, customers, to will better organization result operating continuing actions
this is $XXX total lead well complete as the primarily long-lived fiscal anticipate employee leverage. margins, facility substantially improved a We second program $XXX estimate million These of other be the and asset severance of exit-related and by to from the of initiatives will and will the charges begin to end and program impairments. half million, costs, restructuring We between other employee-related year. this streamlined of consisting fiscal XXXX. infrastructure benefits costs in as This anticipated half first operating
confident We with are across ability well and all to alternate in delivering positioned remain continue capabilities of our care, assets and long-term leading growth. we the sites
X% the to X% to International revenues Finally, increase increase anticipate X% XX%. segment, in profit and we to operating
in We XXXX. Canadian fiscal our are growth first in business continued pleased with anticipate and the quarter performance
We exit of to completion part as exit. also Norway remain the our committed of European
not gains Contributions yet As a segment, Norway fiscal segment. in sell. operating agreement XXXX anticipate well the impact the of $XXX in country In expenses to the in which in we outlook of be included Norway $XXX equity for the Corporate entered only million, remains quarter investments in portfolio the technology Europe million of into the pretax an incorporates as the to reminder, to have within range first $XXX the operations increased related spend. to that McKesson to million are we related Ventures as
We're including and development the pleased our technology growth, technology efficiency. supporting innovation investments, contributions and our of enterprise pace organization, focused with the on from
continue will customer Our to AI the focus experience. on in improving investments
and technology compliance to We and enterprise and operating anticipate an effectively the model model improve the of strategy needs our operating in evaluate development efficiency. to customers the our accelerate of organization support technology of continuity, approach business continue investment increased and to the organization, level We partners. the operating
in be interest range positive recognized million, to Wrapping outlook be $XXX expense to the our the the fiscal to for the reflecting up million, the generic to first anticipate tax discrete $XXX income in XX%, tax balances approximately sourcing $XXX the reflecting the noncontrolling We average first year quarter million approximately of we rates effective items interest loan full and the reflecting XX% ClarusONE's of throughout from and impact rate We portfolio be on quarter. success increased range company's the our anticipate the $XXX to remainder operations. outlook. And of to anticipate of million interest XXXX. in higher will attributable
to not As discrete provide quarterly we items do and the tax tax a difficult therefore, effective timing guidance. are rate and of reminder, predict, amount
to deployment. billion. We anticipate cash flow $X.X cash $X.X flow Turning billion free approximately and of capital to
Our timing, working including day quarter. that will and marks close cash capital impacted resulting the quarter-to-quarter of the metrics from by week the flow vary free of the
Our guidance XXXX. plans billion shares in repurchase reflects $X.X of to approximately fiscal
outstanding XXX million. As we million average XXX activity, of diluted result estimate range to the in a to be share weighted the approximately repurchase of shares
to We invested allocation capital return our our value to disciplined has a XX%. execute This strategy, creating will continue discipline for capital approaching on shareholders. led
revenue up fiscal and compared We as of Fiscal XX% anticipate Wrapping to $XX.XX operating of as XXXX to of XX% growth XX% represents diluted guidance. XX% we profit XXXX, fiscal share growth anticipate XX% to to to per $XX.XX, the growth which prior compared year. XXXX. of earnings to XX%
less year half the assumes of the full earnings. that year the half delivering with contribution XX% than guidance Our of deliver will second the fiscal approximately anticipated, previously first
the our incorporates confident outlook In services closing, our platforms. positions momentum business. We leading in oncology XXXX and across growth fiscal continued biopharma pillars remain in across
will sustain confident the over growth we taking past several now delivered have We the we the are years. actions are
which financial us our shareholder partners allocation the to stable With to have remain that, for to strategy. execute positioned and Q&A. to customers and We our a we and can move value. strong capital deliver foundation, positions We our create sustainable on